Elanco Animal Health Incorporated (NYSE:ELAN) Director Michael J. Harrington Buys 3,500 Shares

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) Director Michael J. Harrington purchased 3,500 shares of the business's stock in a transaction dated Thursday, August 22nd. The shares were purchased at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the purchase, the director now directly owns 81,094 shares of the company's stock, valued at approximately $1,204,245.90. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Elanco Animal Health Trading Down 0.5 %

Shares of Elanco Animal Health stock traded down $0.07 on Monday, reaching $14.50. 3,187,982 shares of the company's stock were exchanged, compared to its average volume of 4,842,229. The firm's 50-day moving average is $14.19 and its two-hundred day moving average is $15.31. The company has a market capitalization of $7.17 billion, a P/E ratio of -5.47, a price-to-earnings-growth ratio of 1.27 and a beta of 1.42. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.96 and a current ratio of 3.29. Elanco Animal Health Incorporated has a 52 week low of $8.52 and a 52 week high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. The firm had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.15 billion. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The business's revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.18 earnings per share. Sell-side analysts predict that Elanco Animal Health Incorporated will post 0.93 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Primecap Management Co. CA increased its stake in Elanco Animal Health by 2.9% in the 4th quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company's stock valued at $753,945,000 after buying an additional 1,431,665 shares during the last quarter. Vanguard Group Inc. boosted its position in Elanco Animal Health by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company's stock worth $737,083,000 after purchasing an additional 467,196 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Elanco Animal Health by 4.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company's stock valued at $360,425,000 after purchasing an additional 852,281 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Elanco Animal Health by 33.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 15,095,179 shares of the company's stock worth $224,920,000 after buying an additional 3,816,514 shares during the last quarter. Finally, Ancora Advisors LLC grew its position in Elanco Animal Health by 1.4% during the first quarter. Ancora Advisors LLC now owns 10,641,194 shares of the company's stock valued at $173,239,000 after buying an additional 143,326 shares during the period. 97.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on ELAN. Piper Sandler cut their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a "neutral" rating on the stock in a report on Monday, July 1st. Barclays reduced their target price on Elanco Animal Health from $23.00 to $21.00 and set an "overweight" rating on the stock in a report on Friday, June 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Elanco Animal Health currently has an average rating of "Moderate Buy" and a consensus price target of $17.57.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.